Leukemia Clinical Trials

CLINICAL TRIAL 19319
InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Condition: Genitourinary
Intervention: Ifosfamide (); Not Applicable (); Radiotherapy (); Taxol (paclitaxel); cisplatin (); paclitaxel ()

CLINICAL TRIAL 19658
A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy
Condition: Malignant Hematology
Intervention: Cedazuridine (); SX-682 (); decitabine (5-aza-2'-deoxycytidine)

CLINICAL TRIAL 19658
A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy
Condition: Malignant Hematology
Intervention: Cedazuridine (); SX-682 (); decitabine (5-aza-2'-deoxycytidine)

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20490
Keystroke: A Randomized Phase II Study of Pembrolizumab (Keytruda) Plus Stereotactic Re-irradiation versus SBRT Alone For Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Condition: Head & Neck
Intervention: Pembrolizumab (Keytruda)

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20632
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients with Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
Condition: Malignant Hematology
Intervention: FK506 (Tacrolimus); MESNA (); PBSC (); Tacrolimus (); Thiotepa (Thioplex); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()

CLINICAL TRIAL 20632
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients with Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)
Condition: Malignant Hematology
Intervention: FK506 (Tacrolimus); MESNA (); PBSC (); Tacrolimus (); Thiotepa (Thioplex); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()

CLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Condition: Malignant Hematology
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()

CLINICAL TRIAL 20733
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzomab Ozogamicin (a conjugated anti-CD22 monoclonal antibody) to Frontline Therapy in Young Adults (ages 18-39 years) with Newly Diagnosed Precusor B-cell ALL
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20731
Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Condition: Cutaneous
Intervention: Afatinib (); BIBW 2992 (Afatinib)

CLINICAL TRIAL 20752
A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); daunorubicin (); gilteritinib ()

CLINICAL TRIAL 20752
A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); daunorubicin (); gilteritinib ()

CLINICAL TRIAL 20870
Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Condition: Gynecological Tumor
Intervention: Aspirin/Placebo (); Avastin (Bevacizumab); Bevacizumab (); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin (); paclitaxel ()

CLINICAL TRIAL 20937
A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib In Refractory Advanced Thymic Carcinoma
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); Sunitinib Malate (SU011248)

CLINICAL TRIAL 21056
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 21192
A Phase 2 Study of the Combination Dostarlimab with Niraparib In Patients with Penile Carcinoma Who Have Progressed Following Chemotherapy
Condition: Genitourinary
Intervention: Dostarlimab (); Niraparib (); TSR-042 (Dostarlimab)

CLINICAL TRIAL 21213
A Single-Arm, Open-Label Phase 1b Study of Hyper-CVAD + Calaspargase pegol in Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: Calaspargase pegol ()

CLINICAL TRIAL 21405
Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in lower Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN)
Condition: Malignant Hematology
Intervention: ACE-536 (Luspatercept); Luspatercept ()

CLINICAL TRIAL 21415
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis
Condition: Malignant Hematology
Intervention: Fedratinib (); Imetelstat (GRN163L); Jakafi (Ruxolitinib); Momelotinib (); Pacritinib (); Ruxolitinib ()

CLINICAL TRIAL 21416
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Condition: Malignant Hematology
Intervention: CLN-049 (); Diphenhydramine (); Hydrocortisone (); Paracetamol (); acetaminophen ()

CLINICAL TRIAL 21450
A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); Gemtuzumab Ozogamicin (); Mylotarg (Gemtuzumab Ozogamicin); daunorubicin ()

CLINICAL TRIAL 90016
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 21752
Chimeric Antigen Receptor T-Cell Therapy: Neurocognitive Effects and Patient-Reported Outcomes
Condition: Multiple
Intervention:

CLINICAL TRIAL 21752
Chimeric Antigen Receptor T-Cell Therapy: Neurocognitive Effects and Patient-Reported Outcomes
Condition: Multiple
Intervention:

CLINICAL TRIAL 21763
MRKR-21-401-OTS - A Phase 1 Study of Allogeneic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cells (MT-401-OTS) Administered to Patients with Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); Bendamustine (); MESNA (); MT-401-OTS (); cyclophosphamide (); cytoxan (cyclophosphamide); decitabine (5-aza-2'-deoxycytidine); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23460
A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors
Condition: Cutaneous
Intervention: Pembrolizumab (Keytruda)

CLINICAL TRIAL 21790
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
Condition: Gastrointestinal Tumor
Intervention: Atezolizumab (Tecentriq); Etoposide (); Paraplatin (carboplatin); carboplatin (); cisplatin (); etoposide ()

CLINICAL TRIAL 21899
Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 and/or PALB2 Mutation
Condition: Multiple
Intervention: CX-5461 ()

CLINICAL TRIAL 21917
A Phase II Study Of Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Overexpressing Gastroesophageal Cancers
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); Herceptin (Trastuzumab); Neratinib (); Oxaliplatin (); Pembrolizumab (Keytruda); Trastuzumab (); eloxatin (Oxaliplatin); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 21956
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
Condition: Immunotherapy
Intervention:

CLINICAL TRIAL 21970
A multicenter, open-label, first-in human (FIH), multiple expansion cohort, Phase 1/2 study to evaluate the safety and efficacy of DR-01 in adult subjects with large granular lymphocytic leukemia
Condition: Malignant Hematology
Intervention: DR-01 ()

CLINICAL TRIAL 21996
An Open-Label, Multicenter, Phase 1b/2 Study of RP1 in Solid Organ Transplant Recipients with Advanced Cutaneous Malignancies
Condition: Cutaneous
Intervention: RP1 ()

CLINICAL TRIAL 21997
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Condition: Cutaneous
Intervention: Not Applicable (); Vismodegib (Erivedge)

CLINICAL TRIAL 22002
A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
Condition: Multiple
Intervention: RMC-6236 ()

CLINICAL TRIAL 22095
A Phase 2 study of Canakinumab in patients with Myelofibrosis
Condition: Malignant Hematology
Intervention: Canakinumab (); Fedratinib (); Jakafi (Ruxolitinib); Momelotinib (); Pacritinib (); Ruxolitinib ()

CLINICAL TRIAL 90038
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22102
A Phase 1b, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors
Condition: Multiple
Intervention: XMT-1660 ()

CLINICAL TRIAL 22318
A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm (SM-AHN)
Condition: Malignant Hematology
Intervention: Avapritinib (); BLU-285 (Avapritinib); Cedazuridine (); decitabine (5-aza-2'-deoxycytidine)

CLINICAL TRIAL 22318
A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm (SM-AHN)
Condition: Malignant Hematology
Intervention: Avapritinib (); BLU-285 (Avapritinib); Cedazuridine (); decitabine (5-aza-2'-deoxycytidine)

CLINICAL TRIAL 22134
AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis
Condition: Immunotherapy
Intervention: Abatacept (); Corticosteroids (); Placebo ()

CLINICAL TRIAL 22190
A phase 1b, open label, multi-center, dose optimization and dose expansion study to assess the safety and efficacy of DFV890 in adult patients with myeloid diseases
Condition: Malignant Hematology
Intervention: DFV890 ()

CLINICAL TRIAL 22263
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or B-cell Non-Hodgkin Lymphoma
Condition: Malignant Hematology
Intervention: AS-1763 ()

CLINICAL TRIAL 22286
Phase 2 Study of KTE-X19 in MRD Positive B-ALL
Condition: Malignant Hematology
Intervention: KTE-X19 (); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22286
Phase 2 Study of KTE-X19 in MRD Positive B-ALL
Condition: Malignant Hematology
Intervention: KTE-X19 (); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22305
First-in-Human Study of STX-478, a Mutant-Selective PI3Ka Inhibitor as Monotherapy and in Combination with Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: 772256 (Palbociclib); Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Ribociclib (); STX478-101 (); fulvestrant ()

CLINICAL TRIAL 22367
The Impact Of Inflammation On HSPC Composition And Disease Progression In Chronic Myelomonocytic Leukemia (CMML INTERCEPT STUDY) SUB-TITLE: Intercepting CMML Disease Progression Driven by Acute Inflammation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22461
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Melphalan (); Ossium HPC (); Radiotherapy (); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22461
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Melphalan (); Ossium HPC (); Radiotherapy (); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22469
A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
Condition: Malignant Hematology
Intervention: AZD0486 ()

CLINICAL TRIAL 22483
Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
Condition: Gastrointestinal Tumor
Intervention: Ezurpimtrostat (GNS561) (); GSK1120212 (Trametinib); Trametinib ()

CLINICAL TRIAL 22538
A Phase 1/2a Multicenter Ascending Dose Study to Evaluate the Safety of HA-1 Minor Histocompatibility Antigen-Reactive TCR-Modified T Cells (BSB-1001) in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); BSB-1001 (); Melphalan (); Radiotherapy (); Thiotepa (Thioplex); busulfan (); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22538
A Phase 1/2a Multicenter Ascending Dose Study to Evaluate the Safety of HA-1 Minor Histocompatibility Antigen-Reactive TCR-Modified T Cells (BSB-1001) in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); BSB-1001 (); Melphalan (); Radiotherapy (); Thiotepa (Thioplex); busulfan (); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22604
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (); RMC-9805 ()

CLINICAL TRIAL 22696
Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-Leukemia
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22696
Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-Leukemia
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23060
A Controlled Multi-Arm Phase 1 Umbrella Study Evaluating the Safety and Feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 Positive Patients Undergoing Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23060
A Controlled Multi-Arm Phase 1 Umbrella Study Evaluating the Safety and Feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 Positive Patients Undergoing Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23058
A Phase I/II Study of Quizartinib in Combination with Decitabine and Venetoclax for the Treatment of Patients with Acute Myeloid Leukemia (AML)
Condition: Malignant Hematology
Intervention: GDC-0199 (Venetoclax); Quizartinib (); Venetoclax (); decitabine (5-aza-2'-deoxycytidine)

CLINICAL TRIAL 23066
An Open-Label, Multi-Center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-Targeting T Cell Engager, in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer and in Patients with Other Relapsed/Refractory Neuroendocrine Carcinoma DAREON-5
Condition: Gastrointestinal Tumor
Intervention: BI 764532 ()

CLINICAL TRIAL 23101
A phase 2 study to investigate the efficacy and safety of CYP-001 in combination with corticosteroids in adults with high-risk acute graft versus host disease
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23143
Trends and Outcomes in HIV-positive Patients Undergoing Treatment for Invasive or Preinvasive Cervical and Other Gynecologic Neoplasias
Condition: Gynecological Tumor
Intervention:

CLINICAL TRIAL 23154
A Prospective, Multicenter, Randomized, Open-Label, Phase II Study of Salvage BCL2i Plus CLAG-M in Relapsed or Refractory Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Cladribine (); Cytarabine (Cytosine Arabinoside); G-CSF (); GDC-0199 (Venetoclax); Novantrone (mitoxantrone); Venetoclax (); mitoxantrone ()

CLINICAL TRIAL 23176
A Phase 2, randomised, open label, multicentre study of an intraperitoneal alpha-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery
Condition: Gynecological Tumor
Intervention: Radspherin ()

CLINICAL TRIAL 23220
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
Condition: Malignant Hematology
Intervention: REM-422 ()

CLINICAL TRIAL 23226
A Prospective Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as an Adjunctive and Maintenance Treatment in Adult Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Condition: Malignant Hematology
Intervention: Mocravimod (); Placebo ()

CLINICAL TRIAL 23226
A Prospective Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as an Adjunctive and Maintenance Treatment in Adult Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
Condition: Malignant Hematology
Intervention: Mocravimod (); Placebo ()

CLINICAL TRIAL 23233
Evaluating the correlation between clonal hematopoiesis chemotherapy induced peripheral neuropathy in patients with gastrointestinal malignancies exposed to oxaliplatin
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23254
A Phase 1/1b Open-Label, Dose-Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor BH-30236 in Adults with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Condition: Malignant Hematology
Intervention: BH-30236 (); GDC-0199 (Venetoclax); Venetoclax ()

CLINICAL TRIAL 23284
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
Condition: Malignant Hematology
Intervention: Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); MESNA (); Mycophenolate Mofetil (); Radiotherapy (); Tacrolimus (); Thymoglobulin (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23307
A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hematologic Malignancies
Condition: Malignant Hematology
Intervention: Dasatinib (BMS-354825); KQB198 ()

CLINICAL TRIAL 23307
A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hematologic Malignancies
Condition: Malignant Hematology
Intervention: Dasatinib (BMS-354825); KQB198 ()

CLINICAL TRIAL 23308
A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Condition: Malignant Hematology
Intervention: AJ1-11095 ()

CLINICAL TRIAL 23318
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
Condition: Sarcoma
Intervention: Pembrolizumab (Keytruda)

CLINICAL TRIAL 23652
A Phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory (R/R) CD19+ hematologic malignancies
Condition: Malignant Hematology
Intervention: Rapamycin (Sirolimus); UB-VV111 ()

CLINICAL TRIAL 23321
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Anitocabtagene autoleucel (); Bortezomib (); CC-4047 (Pomalidomide); Daratumumab (Darzalex); Dexamethasone (); PS-341 (Bortezomib); Pomalidomide (); Velcade (Bortezomib); carfilzomib (Kyprolis); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23360
IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Subjects with Advanced or Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: IFx-Hu2.0 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23369
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58)
Condition: Neurologic Oncology
Intervention: Pembrolizumab (Keytruda); Placebo (); Temodal (Temozolomide); Temozolomide ()

CLINICAL TRIAL 23378
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of AVZO-021 as a single agent and in combination therapy in patients with advanced solid tumors
Condition: Breast
Intervention: 772256 (Palbociclib); AVZO-021 (); Abemaciclib (); Faslodex (fulvestrant); Femara (Letrozole); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Paraplatin (carboplatin); Ribociclib (); Sacituzumab Govitecan (); carboplatin (); fulvestrant ()

CLINICAL TRIAL 23380
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod CAR T Protducts in Heterozygous HLA-A*02 Adult with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Condition: Thoracic
Intervention: A2B543 (); A2B694 (); IL-2 (Interleukin-2); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23436
A Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in Federal Qualified Health Centers
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 23618
Genomic and Immunological Roadmap of Archival HPV Gynecologic Malignancies in Diverse Populations
Condition: Gynecological Tumor
Intervention:

CLINICAL TRIAL 23489
Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23489
Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23502
BMT-CARE: Multimodal Psychosocial Intervention for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23502
BMT-CARE: Multimodal Psychosocial Intervention for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23442
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenace Therapy in Adult Patients with Newly Diagnosed FLT3-ITD (-) Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); Placebo (); Quizartinib ()

CLINICAL TRIAL 23448
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D Mutation
Condition: Multiple
Intervention: Cemiplimab (); Cetuximab (); Erbitux (Cetuximab); Pembrolizumab (Keytruda); QTX3034 (); REGN2810 (Cemiplimab); mFOLFOX6 ()

CLINICAL TRIAL 23453
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: AZD0486 ()

CLINICAL TRIAL 23456
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (CTN 2203)
Condition: Immunotherapy
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); Jakafi (Ruxolitinib); Melphalan (); Mycophenolate Mofetil (); Radiotherapy (); Ruxolitinib (); Tacrolimus (); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()

CLINICAL TRIAL 23456
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (CTN 2203)
Condition: Immunotherapy
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); Jakafi (Ruxolitinib); Melphalan (); Mycophenolate Mofetil (); Radiotherapy (); Ruxolitinib (); Tacrolimus (); busulfan (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); methotrexate ()

CLINICAL TRIAL 23477
Phase 1 Study of Asciminib Maintenance Therapy Following Allogeneic Stem Cell Transplant or Chimeric Antigen Receptor T Cell Therapy (CAR T) to Prevent Relapse in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: Asciminib ()

CLINICAL TRIAL 23479
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: BL-M11D1 ()

CLINICAL TRIAL 23490
Pilot Study to Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventilation (CMV) During Anesthesia for Robotic-Assisted Gynecological and Genitourinary Operative Procedures
Condition: Genitourinary
Intervention:

CLINICAL TRIAL 23547
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogenic CAR-T Cell Therapy, in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma(T-RRex)
Condition: Malignant Hematology
Intervention: WU-CART-007 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()

CLINICAL TRIAL 23556
A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23539
Evaluating the correlation between clonal hematopoiesis and response to regorafenib and nivolumab in patients with refractory metastatic colorectal cancer
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23597
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Participants with Advanced or Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: IFx-Hu2.0 (); Pembrolizumab (Keytruda); Placebo ()

CLINICAL TRIAL 23558
Predictors of Health-Related Quality of Life in Adults with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23558
Predictors of Health-Related Quality of Life in Adults with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23557
Distress in Family Caregivers of Inpatients with Malignant Hematology Diagnoses at Hospital Discharge
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23569
Perceptions and Experiences of Food Insecurity in Patients & Their Informal Caregivers Post Allogeneic Stem Cell Transplant
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23587
A Phase 2, Multicenter, Open-Label Study of Lifileucel (Tumor-Infiltrating Lymphocytes [TIL]) in Participants with Previously Treated Advanced Endometrial Cancer
Condition: Gynecological Tumor
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2 (); Lifileucel (); MESNA (); Proleukin (Interleukin-2); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23590
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment versus Standard-Of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
Condition: Multiple
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); Radiotherapy ()

CLINICAL TRIAL 23591
Prediction of Radiotherapy Benefit Using Genomic-Adjusted Radiation Dose in Pediatric Low Grade Gliomas and Ependymomas
Condition: Neurologic Oncology
Intervention:

CLINICAL TRIAL 23594
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); Eganelisib ()

CLINICAL TRIAL 23594
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); Eganelisib ()

CLINICAL TRIAL 23601
Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): a Randomized, Phase 2 Trial
Condition: Malignant Hematology
Intervention: ASTX727 (); GDC-0199 (Venetoclax); Venetoclax ()

CLINICAL TRIAL 23602
A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: AUTX-703 ()

CLINICAL TRIAL 23636
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
Condition: Gynecological Tumor
Intervention: XmAb541 ()

CLINICAL TRIAL 23645
A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: XB628 ()

CLINICAL TRIAL 23665
ProSalud: A Health Promotion Project to Reduce Cancer Risk in Latinos Living in Rural/Agricultural Communities within Moffitt's Catchment Area
Condition: Healthy Subjects
Intervention:

CLINICAL TRIAL 23659
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Condition: Multiple
Intervention: ARV-806 ()

CLINICAL TRIAL 23660
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention:

CLINICAL TRIAL 23675
A Phase 1, Open-Label, Dose-escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants with Relapsed or Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.
Condition: Malignant Hematology
Intervention: CBX-250 ()

CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()

CLINICAL TRIAL 23710
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); Cusatuzumab (); GDC-0199 (Venetoclax); Venetoclax ()

CLINICAL TRIAL 23740
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23747
Evaluation of SSTR Subtype Expression in Brain Regions via IHC
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 23773
A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
Condition: Malignant Hematology
Intervention: AZD0120 ()

CLINICAL TRIAL 23785
CASCADE: A Single-Arm, Open-Label Clinical Phase II Trial of the Safety and Immunogenicity of PDS0101 in People Living with HIV
Condition: N/A
Intervention:

CLINICAL TRIAL 23939
Distinguishing Breast and Cutaneous Tumors
Condition: Breast
Intervention:

CLINICAL TRIAL 23952
Treatment Effect vs. Tumor Progression - Quantitative Analysis Using Machine Learning
Condition: Neurologic Oncology
Intervention:

CLINICAL TRIAL 24006
Perioperative nurses knowledge retention of annual robotic-assisted surgical education
Condition: Multiple
Intervention: